University of Minnesota Study Reveals Fecal Transplants Drastically Reduce Mortality in Severe C. Difficile Patients

A new University of Minnesota study shows fecal microbiota transplants can reverse systemic inflammation and reach 78% survival in fulminant C. difficile cases.

By: AXL Media

Published: Apr 7, 2026, 6:34 AM EDT

Source: Information for this report was sourced from University of Minnesota Medical School.

Standardized Microbiota Protocol Targets Fatal Intestinal Infections

Medical researchers at the University of Minnesota have pioneered a treatment protocol using fecal microbiota transplantation to combat the most aggressive forms of Clostridioides difficile. This specific infection triggers a sepsis-like state that frequently proves fatal when traditional antibiotic therapies fail to stabilize the patient. By implementing a standardized approach, clinicians observed a rapid decline in systemic inflammatory markers among participants, providing a non-surgical alternative for individuals whose physical condition has deteriorated to a critical point.

Significant Survival Gains in High Risk Patient Groups

The study monitored 18 critically ill patients who were not responding to intensive antibiotic treatments and were deemed high-risk for surgical procedures. Following the administration of the specialized transplant, the group achieved a 30-day survival rate of 78 percent, marking a significant milestone in treating a disease that kills approximately 15,000 people in the United States every year. These results suggest that the intervention can effectively halt the downward spiral of fulminant infections by restoring the microbial communities typically destroyed by heavy antibiotic use.

Strategic Importance of Immediate Treatment Accessibility

Dr. Alexander Khoruts, who leads the Microbiota Therapeutics Program, emphasized that the window for successful intervention is exceptionally narrow due to the extreme severity of the illness. To address this, the university utilizes an on-site manufacturing facility that produces transplant units under pharmaceutical standards, maintaining a cryobank to ensure the therapy is available for immediate use. According to Khoruts, having these units on hand is essential because the speed of administration is a primary factor in patient outcomes when they are in a deteriorating state.